Company Profile
Updated: 06-NOV-09Astellas Pharma S.A.S.
International Private company
Le Malsherbe, 114 rue Victor Hugo, Levallois Perret, F-92686 cedex, France
()33 01 55 91 75 00, 33 01 55 91 75 69 fax, http://www.astellas-europe.co.uk
Primary SIC: Drugs, Proprietaries And Sundries, Primary NAICS: Drugs and Druggists' Sundries Merchant Wholesalers
Description: Wholesale: Research into and wholesale trade in pharmaceuticals, including antibiotics, metabolic drugs and circulatory system agents
View this company profile - Now for a Limited Time, try Goliath Company Profiles
Free for 3 Days!
Maxygen Reports Third Quarter 2009 Financial Results.(Financial report)
Blood Weekly; 11/19/2009; 1222 words; ...Therapeutics LLC, the company's joint venture with Astellas Pharma Inc., and Maxygen's subsequent restructuring...acquire all of Maxygen's ownership interest in...Investing, Technology, Astellas Pharma Inc., Bayer Healthcare...
Aradigm Announces Third Quarter 2009 Financial Results.(Financial report)
Biotech Week; 11/18/2009; 1285 words; ...milestone payment upon initial U.S. commercialization by Zogenix...commercialization in the U.S. by Zogenix and its partner, Astellas Pharma US, Inc. We are continuing...said Igor Gonda, the Company's CEO and President. About Aradigm...
Astellas Pharma Europe Announces the International Foundation for Dermatology a Winner of the Changing Tomorrow 2009 Awards.
Biotech Week; 11/18/2009; 607 words; Astellas Pharma Europe, the European...subsidiary of Tokyo-based Astellas Pharma Inc, one of the world's top 20 pharmaceutical...uphold the company's strong ethical principles...initiatives is the Astellas Pharma Europe Foundation...
Seattle Genetics Initiates Phase I Clinical Trial of Antibody-Drug Conjugate SGN-75.
Business Wire; 11/16/2009; 1296 words; ...that utilizes the company's proprietary technology...autoimmune disease. The company's lead product candidate...Agensys, a subsidiary of Astellas Pharma. More information can be...contained in the company's 10-Q for the quarter ended...
XenoPort to Release Third Quarter Financial Results on November 3, 2009.(Financial report)
Investment Weekly News; 11/14/2009; 786 words; ...candidates that utilize the body's natural nutrient transport...XP13512, in collaboration with Astellas Pharma Inc. and GlaxoSmithKline...currently reviewing GSK's NDA for XP13512 as a potential...United States. XenoPort's product candidates are also...
Recent News Articles
- Investigators at Astellas Pharma, Inc. publish new data on liquid chromatography.
Biotech Week - September 23, 2009 - IN BRIEF: Ridaura Tiltab to cease.(Astellas Pharma Inc.)(Brief article)
Chemist & Druggist - September 12, 2009 - Researchers from Astellas Pharma, Inc. detail findings in tachycardia.(Report)
Biotech Week - August 26, 2009 - Japanese pharma concern Astellas Pharma has formed a joint venture with US biopharma firm Maxygen to develop multiple protein pharmaceutical programmes, including Maxygen's MAXY-4, for the treatment of autoimmune diseases and transplant rejection.(Pharma briefs)(Brief article)
Chemistry and Industry - July 27, 2009
Why Purchase This Company Profile?
- Sales prospecting
- Competitive analysis
- Vendor & supplier evaluation
- Customer evaluation and analysis
- Strategic planning
